Study demonstrates clinical effectiveness of Systagenix ADAPTIC TOUCH as a primary wound contact layer

NewsGuard 100/100 Score

Systagenix announced today (20 April 2011) that a recent product evaluation published in the journal Wounds UK, Vol 7, No 1, demonstrates the clinical effectiveness of ADAPTIC TOUCH® as a primary wound contact layer that addresses the needs of both patients and healthcare professionals.

The study reviewed a cross section of sources including in vitro and in vivo studies, focus groups and case reports on the use of ADAPTIC TOUCH® in treating acute or chronic wounds. The evidence base shows clearly to clinicians that ADAPTIC TOUCH® offers a non-adherent silicone-based primary contract layer that provides ease of application, free flow of exudate to the secondary dressing, and minimal or no trauma on removal. As demonstrated in the study, the dressing stays in place in articulating surfaces, allowing mobilisation and rehabilitation to take place.

Steve Atkinson, Systagenix CEO, said: "This product review brings together numerous studies to validate the effectiveness of ADAPTIC TOUCH® dressings. ADAPTIC TOUCH® is a primary silicone wound contact layer that provides patients with comfort and for healthcare professionals; the result is a primary silicone dressing that minimises tissue damage and adherence to the secondary dressing, making it easy, reliable and successful to work with."

Source:

Systagenix

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
U-M study reveals potential pathway to reverse lung fibrosis